Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer

NCT02725541 is registered in ClinicalTrials.gov with Jenny C. Chang, MD as lead sponsor.

NCT NCT02725541
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02725541 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer
Lead sponsor
Jenny C. Chang, MD
Phase
Phase 2
Overall status
Withdrawn
Start date
March 31, 2016
Completion date
May 31, 2019
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer